Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Biomarin Pharmaceutical Inc (NASDAQ: BMRN) closed at $58.66 up 2.11% from its previous closing price of $57.45. In other words, the price has increased by $2.11 from its previous closing price. On the day, 1.7 million shares were traded. BMRN stock price reached its highest trading level at $58.8 during the session, while it also had its lowest trading level at $57.415.
Ratios:
For a deeper understanding of Biomarin Pharmaceutical Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.86 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.21. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 5.56. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
On November 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $95.Wolfe Research initiated its Outperform rating on November 15, 2024, with a $95 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 20 ’25 when Burkhart Erin sold 1,786 shares for $59.31 per share. The transaction valued at 105,928 led to the insider holds 14,173 shares of the business.
Burkhart Erin bought 1,786 shares of BMRN for $105,928 on May 20 ’25. On May 02 ’25, another insider, Hubbard Cristin, who serves as the EVP, Chief Commercial Officer of the company, sold 273 shares for $64.92 each. As a result, the insider received 17,723 and left with 32,700 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRN now has a Market Capitalization of 11263600640 and an Enterprise Value of 10435317760. As of this moment, Biomarin’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.37, and their Forward P/E ratio for the next fiscal year is 12.80. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.53. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.70 while its Price-to-Book (P/B) ratio in mrq is 1.87. Its current Enterprise Value per Revenue stands at 3.406 whereas that against EBITDA is 10.925.
Stock Price History:
The Beta on a monthly basis for BMRN is 0.35, which has changed by -0.35799497 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, BMRN has reached a high of $93.04, while it has fallen to a 52-week low of $52.93. The 50-Day Moving Average of the stock is 1.82%, while the 200-Day Moving Average is calculated to be -6.13%.
Shares Statistics:
For the past three months, BMRN has traded an average of 2.25M shares per day and 1759100 over the past ten days. A total of 192.00M shares are outstanding, with a floating share count of 189.13M. Insiders hold about 1.50% of the company’s shares, while institutions hold 97.83% stake in the company. Shares short for BMRN as of 1755216000 were 4956158 with a Short Ratio of 2.20, compared to 1752537600 on 6109799. Therefore, it implies a Short% of Shares Outstanding of 4956158 and a Short% of Float of 3.3099998.
Earnings Estimates
The stock of Biomarin Pharmaceutical Inc (BMRN) is currently in the spotlight, with 18.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.96, with high estimates of $1.14 and low estimates of $0.75.
Analysts are recommending an EPS of between $4.85 and $3.39 for the fiscal current year, implying an average EPS of $4.3. EPS for the following year is $5.45, with 21.0 analysts recommending between $6.22 and $4.57.
Revenue Estimates
A total of 21 analysts believe the company’s revenue will be $789.08M this quarter.It ranges from a high estimate of $822M to a low estimate of $769.81M. As of the current estimate, Biomarin Pharmaceutical Inc’s year-ago sales were $745.74MFor the next quarter, 21 analysts are estimating revenue of $814.44M. There is a high estimate of $835M for the next quarter, whereas the lowest estimate is $759M.
A total of 26 analysts have provided revenue estimates for BMRN’s current fiscal year. The highest revenue estimate was $3.21B, while the lowest revenue estimate was $3.08B, resulting in an average revenue estimate of $3.17B. In the same quarter a year ago, actual revenue was $2.85BBased on 25 analysts’ estimates, the company’s revenue will be $3.45B in the next fiscal year. The high estimate is $3.7B and the low estimate is $3.2B.
